Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer

Phase 2

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: paclitaxel

First Posted Date: 2010-07-16

Last Posted Date: 2012-10-24

Lead Sponsor: University of Kansas

Registration Number: NCT01163929

Meta-analysis of Efficacy of Topotecan

Completed

Conditions: Cervical Intraepithelial Neoplasia

Interventions: Drug: paclitaxel
Drug: cisplatin
Drug: topotecan

First Posted Date: 2010-07-12

Last Posted Date: 2010-07-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT01160185

Molecular Triaging of Newly Diagnosed Breast Cancer

Not Applicable

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Fluorouracil
Drug: Doxorubicin
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Bevacizumab

First Posted Date: 2010-07-09

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01159236

A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)

Phase 4

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: bevacizumab [Avastin]
Drug: paclitaxel

First Posted Date: 2010-07-05

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT01156961

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Docetaxel
Drug: Cetuximab
Drug: Cisplatin
Radiation: Radiotherapy (RT)
Drug: Fluorouracil
Other: Chemotherapy

First Posted Date: 2010-07-01

Last Posted Date: 2024-12-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 128

Registration Number: NCT01154920

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant Therapy for Ovarian Cancer

Phase 2

Completed

Conditions: Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Bevacizumab

First Posted Date: 2010-06-22

Last Posted Date: 2021-02-09

Lead Sponsor: Jason D. Wright

Target Recruit Count: 32

Registration Number: NCT01146795

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
University of Virginia, Charlottesville, Virginia, United States

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Biological: HER2Bi-armed activated T cells
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: paclitaxel
Other: laboratory biomarker analysis
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery

First Posted Date: 2010-06-22

Last Posted Date: 2023-04-27

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 8

Registration Number: NCT01147016

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer

Not Applicable

Terminated

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Carcinoma

Interventions: Drug: Hyperthermic intraperitoneal chemotherapy with Carboplatin
Other: Isotonic saline (perfusate)
Procedure: Surgery
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2010-06-15

Last Posted Date: 2019-07-30

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 10

Registration Number: NCT01144442

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Esophageal Adenocarcinoma
Metastatic Esophageal Squamous Cell Carcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Recurrent Esophageal Adenocarcinoma
Recurrent Esophageal Carcinoma
Recurrent Esophageal Squamous Cell Carcinoma
Recurrent Gastroesophageal Junction Adenocarcinoma
Stage IV Esophageal Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Biological: Cixutumumab
Other: Pharmacological Study
Drug: Paclitaxel

First Posted Date: 2010-06-11

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 94

Registration Number: NCT01142388

Locations: 🇺🇸
Carle Cancer Institute Normal, Normal, Illinois, United States
🇺🇸
Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States
🇺🇸
OSF Saint Francis Radiation Oncology at Pekin, Pekin, Illinois, United States

and more 229 locations

A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer

Phase 2

Withdrawn

Conditions: Neoplasms, Breast

Interventions: Biological: Trastuzumab
Drug: Lapatinib
Drug: Docetaxel
Drug: Paclitaxel
Drug: Vinorelbine

First Posted Date: 2010-06-07

Last Posted Date: 2013-03-13

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT01137994

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy